Original Article
Pterostilbene inhibits hepatocellular carcinoma proliferation and HBV replication by targeting ribonucleotide reductase M2 protein

Rui Wang1,2*, Zhijian Xu3*, Jiaping Tian1,2, Qian Liu1, Jingwen Dong1, Lijuan Guo1, Boning Hai1, Xia Liu1, Hangping Yao4, Zhi Chen4, Junjie Xu5, Lijun Zhu6, Haiyi Chen7, Tingjun Hou7, Weiliang Zhu3, Jimin Shao1,2

1Department of Pathology & Pathophysiology, and Cancer Institute of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; 2Zhejiang University Cancer Center, Key Laboratory of Disease Proteomics of Zhejiang Province, Key Laboratory of Cancer Prevention and Intervention of China National Ministry of Education, Zhejiang University School of Medicine, Hangzhou, China; 3Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; 4State Key Laboratory of Infectious Disease Diagnosis and Treatment, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; 5Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; 6Key Laboratory of Pancreatic Disease of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; 7Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. *Co-first authors.

Received February 2, 2021; Accepted May 10, 2021; Epub June 15, 2021; Published June 30, 2021

Abstract: Hepatocellular carcinoma (HCC), one of the most deadly diseases all around the world. HBV infection is a causative factor of HCC and closely associated with HCC development. Ribonucleotide reductase (RR) is a key enzyme for cellular DNA synthesis and RR small subunit M2 (RRM2) is highly upregulated in HCC with poor survival rates. We have previously shown that HBV can activate the expression of RRM2 and the activity of RR enzyme for the viral DNA replication in host liver cells. Thus, RRM2 may be an important therapeutic target for HCC and HBV-related HCC. Pterostilbene, a natural plant component, potently inhibited in vitro RR enzyme activity with the IC50 of about 0.62 μM through interacting with RRM2 protein, which was much higher than current RRM2 inhibitory drugs. Pterostilbene inhibited cell proliferation with an MTT IC50 of about 20-40 μM in various HCC cell lines, causing DNA synthesis inhibition, cell cycle arrest at S phase, and accordingly apoptosis. On the other hand, the compound significantly inhibited HBV DNA replication in HBV genome integrated and newly transfected HCC cells, and the EC50 for inhibiting HBV replication was significantly lower than the IC50 for inhibiting HCC proliferation. Notably, pterostilbene possessed a similar inhibitory activity in sorafenib and lamivudine resistant HCC cells. Moreover, the inhibitory effects of pterostilbene against HCC proliferation and HBV replication were significantly reversed by addition of dNTP precursors, suggesting that RR was the intracellular target of the compound. Finally, pterostilbene effectively inhibited HCC xenograft growth with a relatively low toxicity in nude mouse experiments. This study demonstrates that pterostilbene is a novel potent RR inhibitor by targeting RRM2. It can simultaneously inhibit HCC proliferation and HBV replication with a potential new use for treatment of HCC and HBV-related HCC.

Keywords: Hepatocellular carcinoma (HCC), hepatitis B virus related hepatocellular carcinoma (HBV-related HCC), pterostilbene, ribonucleotide reductase small subunit M2 (RRM2), DNA synthesis inhibition

Introduction
Hepatocellular carcinoma (HCC) is one of the most deadly diseases all around the world [1]. Hepatitis B virus (HBV) infection is the leading cause of incident cases of liver cancer and deaths, especially in East Asia and Africa [2]. Early-stage HCC is usually treated with surgery, and in some cases liver transplantation is required. However, most patients present with unresectable advanced liver cancer, which requires local treatment or systemic therapy [3]. Unfortunately, systemic therapies for HCC are still limited and prognosis for advanced
Pterostilbene inhibits HCC and HBV by targeting RRM2

HCC generally poor. Novel anti-HCC and anti-HBV-related HCC agents with novel targets or mechanisms are still urgently needed.

Ribonucleotide reductase (RR) catalyzes the conversion of ribonucleotides (NDPs) to deoxyribonucleotides (dNDPs), which are the building blocks for DNA synthesis and thus indispensable for cell proliferation. The holoenzyme of RR consists of large subunit M1 (RRM1) and small subunit M2 (RRM2) or RRM2B [4]. Pan-cancer expression profiling studies showed that the expression of RRM2 and RRM1 are upregulated in multi-types of cancers, and inhibition of RR activity has been proven to be an important anticancer strategy [5-7]. It has been shown previously that in HCC tissues RRM2 is upregulated compared with adjacent normal liver tissues [7, 8], and HBV which has no RR genes can activate RRM2 expression and RR enzyme activity in host liver cells thereby contributing to HBV DNA replication and HCC proliferation [9-11]. The high expression of RRM2 may be a poor prognostic factor for HCC and HBV-related HCC patients as well [12]. Therefore, RRM2 has been assumed to be a promising therapeutic target for HCC and especially HBV-related HCC.

Several RRM2 inhibitors are currently clinically used for anticancer and antivirus therapy [5]. Hydroxyurea (HU), a representative RRM2 inhibitor, is used in clinical treatments for glioblastoma, chronic myelogenous leukemia, acute myelocytic leukemia, and sickle cell anemia alone or combined with other drugs for decades [13-16]. Recently, N-(4-(3,4-dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide (COH29) was shown to possess higher RRM2 inhibitory activity and undergoes an anti-cancer phase I clinical trial [17]. We have also identified osalmid together with its derivative 4-Cyclopropyl-2-fluoro-N(4-hydroxyphenyl) benzamide (YZ51) as potent inhibitors of RRM2 against HBV replication and HCC proliferation, respectively [11]. However, the target specificity, efficacy, and safety of these RRM2 inhibitors still need to be improved.

Pterostilbene (4-[(E)-2-(3,5-Dimethoxyphenyl) ethenyl]phenol) is known as a natural plant product and primarily found in blueberries and grapes [18]. It is a dimethylated derivative of resveratrol but has a much greater bioavailability compared with resveratrol [19]. It has been known that pterostilbene possesses multiple biological activity including antitumor effects [20]. In this study, using RRM2 3-dimentional structure-based computer-assisted screening of drug-like compound libraries, RR enzyme activity and cellular assays, as well as target and action mechanism validations, we for the first time identified pterostilbene as a potent inhibitor for RR activity and HBV DNA replication by interacting with RRM2. It simultaneously inhibited HCC proliferation and HBV replication potently. Mouse xenograft experiments showed that the compound effectively inhibited HCC cell growth with a relative low toxicity in vivo. Thus, the findings suggest a potential novel use of pterostilbene for treatment of HCC and especially HBV-related HCC.

Material and methods

Compounds

Pterostilbene (CAS Registry Number: 537-42-8) and COH29 (CAS Registry Number: 1190932-38-7) were bought from Topscience (Shanghai, China). Hydroxyurea (HU) was bought from Sigma-Aldrich (St. Louis, MO). Sorafenib was bought from Selleck (Shanghai, China). Lamivudine (2’-3’desoxy-3’-thiocytidine, 3TC) was bought from GlaxoSmithKline (Brentford, London).

Virtual screening

The crystal structure of RRM2 protein was retrieved from the protein data bank (PDB code: 3OLJ), and Glide5.5 (Schrödinger, LLC, New York, NY, USA) was used for docking. Remove the crystallographic water molecules in 3OLJ. Select F244, D271, R330 and E334 to define the center of the grid box.

Cell culture and transfection

Huh7 and Hep3B, the human hepatocarcinoma cell lines were purchased from the Cell Bank (Shanghai, China), HepG2, the human hepatocarcinoma cell line was purchased from the ATCC. HepG2.2.15, the human hepatocarcinoma cell line (contains 1.3-copy HBV genome), was purchased from the China Center for Type Culture Collection (CCTCC, Wuhan, China). The sorafenib-resistant HepG2 cells (HepG2-SR) and its counterpart wild-type HepG2 cells (HepG2-WT) were kindly provided by Dr. Xiujun...
Pterostilbene inhibits HCC and HBV by targeting RRM2

Cai [21]. Culture conditions and cell transfection method refer to the previous introduction [11].

**RR activity measurements**

The expression and purification method of RRM1 and RRM2 proteins refer to the previous introduction [22]. A dCDP formation assay was used in RR activity measurement [22, 23]. The calculation of RR activity and inhibition analysis refer to our previous introduction [11].

**Binding analysis using fluorescence quenching**

To assay the binding between small compounds and proteins as described previously [24]. Pterostilbene was titrated into a solution of 1 μM RRM2 at 2.5-100 μM in two fold increments. The emission spectra were recorded over 290-400 nm using a fluorescence spectrophotometer. The K\textsubscript{D} value was calculated as described previously [24].

**Cancer cell growth inhibition assays**

Cells were seeded into 96-well tissue culture plates at 5,000 cells per well. The next day, an equal volume of 2X drug-containing media was added. The cells were cultured for 3 additional days, and then cell growth was determined by MTT assays, and the results were measured at 490 nm.

**Clonogenic assays**

Cells were plated in 6-well plates at 10,000 cells per well, treated with a serial concentrations of pterostilbene for 14 days. Fix the colonies in methanol for 30 minutes and stain the colonies with 0.5% crystal violet for 30 minutes. The number of colonies (>50 cells) were scored using optical microscope. Colony formation rate was calculated as the number of colonies/10,000 × 100%.

**Apoptosis analyses**

Cells were plated in 6-well plates and treated with a series of concentrations of pterostilbene for 48 h. Then, stain the treated cells with V-FITC and PI for 30 minutes. Apoptosis was determined using Focusing Cytometer (FC500 MPL Beckman Coulter).

**Determination of HBV DNA**

HCC cells were seeded in 6-well plates. The next day, the cells were treated with a series concentrations of pterostilbene for 3 days, and then the culture media were changed with fresh pterostilbene and treated for another 3 days. After totally 6-day exposures, the cells were collected. As described previously [25], total DNA was purified from the cultured cells with the NucleoSpin DNA RapidLyse kit (Macherey Nagel, Germany). Measure the HBV DNA levels using Real-time polymerase chain reaction (Q-PCR). Sense and antisense primers were (fwd: GTTGCCCGTTGCTCTAATT, rev: GGAGGTACATACTAGAGTTCCCTTG). Q-PCR was performed with LightCycler 480 SYBR Green mix kit (Roche) using the 480Q-PCR System (Roche).

**EdU incorporation assays**

Cells were seeded in 96-well plates. The next day treat the cells with a serial concentrations of pterostilbene for 24 h, then assay the DNA synthesis by the Cell-Light EdU DNA cell proliferation kit (RiboBio Co., China). Images of the cells were captured with a fluorescence microscope.

**Cell cycle analyses**

Plate the cells in 6-well plates and treat the cells with pterostilbene for 24 h. Cells were fixed in 70% ethanol at -20°C over night. Wash the cells for two times in PBS and staine with RNase A and PI for 30 min. Focusing Cytometer (FC500 MPL Beckman Coulter) was used to determine the cell cycle distribution.

**Immunoprecipitation coupled with HPLC/MS/MS analysis**

The HepG2.2.15 cells were transfected with the expression vectors for FLAG-EV or FLAG-RRM2 [26]. Then the transfected cells were treated with or without pterostilbene for 24 h. Wash the cells for three times in PBS. The cell lysates were then analyzed by immunoprecipitation using anti-FLAG\textsuperscript{®} M2 magnetic beads (Sigma-Aldrich). The eluted protein was verified by western blotting with FLAG antibody (CST). The pterostilbene bound to the eluted protein was measured using HPLC/MS/MS at Zhejiang University Analysis Center of Agrobiology and...
Environmental Science. HPLC/MS/MS analyses were performed using an Agilent 6460 triple quadrupole mass spectrometer (Agilent Technologies, USA) equipped with an electrospray ionization (ESI) source, operated in the negative ion multiple-reaction monitoring (MRM) mode. Agilent Mass Hunter Workstation was used for data acquisition and processing [27].

Mouse tumor xenograft experiments

4-week old nude mice (nu/nu, male), brought from Shanghai SLAC Laboratory Animal Co., China) were subcutaneously injected with $1 \times 10^7$ HepG2 cells on their right flanks. After the tumors’ size reached 100 mm$^3$, each mouse were treated with pterostilbene (50 or 100 mg/kg/day) dissolved in the solvent DMSO by intraperitoneal injection for 2 weeks. Tumor sizes were recorded by measurement of two perpendicular diameters of the tumors during the 2-week period by the formula $1/2 \times \text{width}^2 \times \text{length}$. After 2 weeks harvest the tumors and weigh. The animal experiments were allowed in the ethical approval with the Laboratory Animals Welfare Ethics Review Committee of Zhejiang University (ZJU20170522).

Measurements of serum ALT and AST activity

After 2-week treatments, collect serum samples from each group of the mice. The ALT (Alanine aminotransferase) and AST (Aspartate aminotransferase) activities were measured at Zhejiang Chinese Medical University Laboratory Animal Research Center.

Histopathological examination

Fix the heart, liver, spleen, lung, and kidney tissues of mice in formalin, embed in paraffin, and cut into 3-5 μm sections, stain with hematoxylin and eosin (H&E), and examine by optical microscope at × 200 magnification.

Statistical analysis

Data were analyzed with GraphPad Prism 8.0.1, all values were expressed as the mean ± SD (standard deviation). The significance of the data was determined by the 2-tailed Student’s $t$ test. $P$ values < 0.05 were considered significant.

Results

Pterostilbene inhibits RR enzyme activity by interacting with RRM2 protein

Using computer-aided screening of small molecule compounds, subsequent RR enzyme activity assays and fluorescence quenching analyses, we identified a compound, pterostilbene (Figure 1A and 1B), as a RRM2 inhibitor. The concentration of pterostilbene inhibits the in vitro recombinant RR enzyme (RRM2 and RRM1 proteins) activity to 50% ($IC_{50}$) was 0.62±0.07 μM, which was 150-fold and 20-fold lower than that of HU (the representative RRM2 inhibitory drug) and COH29 (the known most potent RRM2 inhibitory drug presently in an anti-cancer phase I clinical trial), respectively (Figure 1C and Table 1).

The binding of pterostilbene to RRM2 protein was assessed using a fluorescence quenching assay [24] (Figure 1D and 1E). To investigate whether pterostilbene bound to RRM2 in HCC cells, HepG2.2.15 cells were transfected with FLAG-EV or FLAG-RRM2 expression plasmids and followed by treated with or without pterostilbene. The cell lysates were then analyzed by immunoprecipitation-western blotting using FLAG antibody combined with HPLC/MS/MS detection. The results showed that pterostilbene bound to the RRM2 protein (Figure 1F and 1G), but not to the irrelevant protein JMJD5 as a negative control in the HepG2.2.15 cells (Figure S1). The results indicated that pterostilbene inhibits RR enzyme activity by targeting RRM2 protein.

Pterostilbene exhibits an anti-proliferative effect on HCC cells and HBV genome-integrated HCC cells through inhibiting DNA synthesis

To determine the concentration dependence of the growth-inhibitory activity of pterostilbene, in comparison to the RRM2 inhibitors HU and COH29 and the first-line anti-HCC drug sorafenib, four established HCC cell lines were exposed to a full concentration range of each compound for 72 h, respectively (Figure 2A). As Table 2 shown, the concentration of pterostilbene reduces these HCC cell viability to 50% ($IC_{50}$) were at 20 to 30 μM levels, much potent than HU, similar to COH29, and a few fold less effective than that of sorafenib. Notably, pterostilbene had a better inhibitory effect than HU.
Pterostilbene inhibits HCC and HBV by targeting RRM2

A

B

C

D

E

F

G
Pterostilbene inhibits HCC and HBV by targeting RRM2

Figure 1. Pterostilbene inhibits RR enzyme activity by targeting RRM2. A. Chemical structure of pterostilbene. B. Docking model showing the interaction between pterostilbene and key residues of RRM2 (PDB: 3OLJ). The protein structure is shown in blue cartoon. Hydrogen bond is shown in red dashed line. C. Sigmoidal dose-response curves and IC$_{50}$ values of pterostilbene (0.3125 to 20 μM), COH29 (5 to 160 μM), and HU (11.71875 to 1500 μM) for inhibition of RR activity. D. Quenching of the tryptophan fluorescence of RRM2 by pterostilbene. Tryptophan fluorescence spectra of RRM2 (1 μM in PBS buffer) at a serial concentrations of pterostilbene (2.5-100 μM). E. Variation of the extent of fluorescence quenching [(F$_0$-F)/F$_0$, where F$_0$ and F are the fluorescence intensities of RRM2 at 325 nm in the absence and in the presence of pterostilbene, respectively]. F. HepG2.2.15 cells were transfected with FLAG-EV or FLAG-RRM2 expression plasmids, then treated with or without 20 μM pterostilbene for 24 h. The cell lysates were analyzed by immunoprecipitation using anti-FLAG magnetic beads followed by western blotting with FLAG antibody. G. The pterostilbene bounded to the RRM2 protein was detected by HPLC/MS/MS, the retention time for pterostilbene was 3.34 min. RR: Ribonucleotide reductase; RRM2: Ribonucleotide reductase small subunit M2; IC$_{50}$: The concentration of compound inhibits the in vitro recombinant RR enzyme (RRM2 and RRM1 proteins) activity to 50%; HU: Hydroxyurea; PBS: phosphate buffer saline. Results are presented as the mean ± SD of triplicate experiments, IP, immunoprecipitation.

Table 1. IC$_{50}$ values of pterostilbene, HU, and COH29 for inhibition of RR activity

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC$_{50}$ (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pterostilbene</td>
<td>0.62±0.07</td>
</tr>
<tr>
<td>HU</td>
<td>98.17±11.94</td>
</tr>
<tr>
<td>COH29</td>
<td>14.13±1.26</td>
</tr>
</tbody>
</table>

IC$_{50}$: The concentration of compound inhibits the in vitro recombinant RR enzyme (RRM2 and RRM1 proteins) activity to 50%; HU: Hydroxyurea.

and COH29 on the HBV-genome integrated HCC cell line HepG2.2.15. Colony formation assays and apoptosis analyses also showed that pterostilbene potently inhibited the proliferation and induced the apoptosis of HepG2.2.15 cells in a dose-dependent manner (Figure 2B-E).

To further investigate the cellular mechanism of action of pterostilbene, HepG2.2.15 cells were treated with different concentrations of the compound for 24 h. EdU incorporation and flow cytometry analyses showed that the treatments dose-dependently inhibited DNA synthesis (Figure 2F and 2G) and induced cell cycle S-phase arrest (Figure 2H and 2I), respectively, in HepG2.2.15 cells. The results were well in accordance with the consequence of RR function inhibition.

Pterostilbene possesses a similar inhibitory effect against sorafenib-resistant and wild-type HCC cells

Drug resistance is a major drawback of sorafenib in clinical HCC treatment. A strain of sorafenib-resistant HepG2 cells (HepG2-SR) and its parental wild-type HepG2 cells (HepG2-WT) [21], were used to evaluate the ability of pterostilbene to overcome sorafenib resistance. As determined by MTT assays (Figure 3 and Table 3), pterostilbene displayed a similar anti-proliferative effect against both HepG2-SR and HepG2-WT cells, in comparison with the resistance of sorafenib in the cells.

Pterostilbene inhibits HBV DNA replication in HBV genome-integrated and transfected HCC cells and overcomes lamivudine resistance

In order to determine whether pterostilbene can inhibit HBV replication, we assessed its inhibitory effects on HBV DNA replication in the HBV-genome integrated HCC cell line HepG2.2.15 and the HCC cell line HepG2 transfected with 1.3-copy HBV DNA. The results showed that pterostilbene significantly inhibited HBV DNA replication in a dose-dependent manner after 6-day treatments (Figure 4A, 4B and 4C). The EC$_{50}$ values for inhibiting HBV DNA replication by 50% as determined by Q-PCR measurements were about 4 fold lower than the IC$_{50}$ for the viability of HepG2.2.15 cells as determined by MTT assays, indicating that HBV DNA replication is more sensitive to pterostilbene than the host HepG2.2.15 cell proliferation.

Lamivudine (3TC) is the first nucleoside analogue drug for hepatitis B treatment by inhibiting HBV DNA polymerase. To further evaluate whether pterostilbene could overcome 3TC-resistant, HepG2 cells were transfected with the HBV DNA plasmids (wild-type or 3TC resistance mutant) [11]. Then, the HepG2 cells were treated with a series concentrations of pterostilbene or 3TC for 6 days, and then the amount of HBV DNA in the cells was evaluated by Q-PCR assays. As shown in Figure 4C, 4D and Table 5,
Pterostilbene inhibits HCC and HBV by targeting RRM2

A

HepG2

HepG2.2.15

Huh7

Hep3B

B

Pterostilbene

0μM

1.25μM

2.5μM

5μM

HepG2.2.15

C

Clone formation rate (%)

D

Pterostilbene

0μM

10μM

20μM

40μM

HepG2.2.15
Pterostilbene inhibits HCC and HBV by targeting RRM2

Figure 2. Pterostilbene inhibits HCC proliferation through inhibiting DNA synthesis. A. The anti-proliferation activities of pterostilbene, HU, sorafenib and COH29 for HCC cell lines (HepG2, HepG2.2.15, Huh7, and Hep3B). Treat the cells with compound for 72 h, and quantitate the cell viability by MTT assays. B, C. Treat the HepG2.2.15 cells with pterostilbene (1.25, 2.5, and 5 μM) for 14 days, and the colony formation rates were measured. D, E. Treat the HepG2.2.15 cells with pterostilbene (10, 20, and 40 μM) for 48 h, and the apoptosis rates were determined. F, G. Treat the HepG2.2.15 cells with pterostilbene for 24 h, and then the newly synthesized DNA amounts were measured by the EdU incorporation assays. Red fluorescence: the amount of newly synthesized DNA, blue fluorescence: the total number of nuclei stained by DAPI. H, I. Treat the HepG2.2.15 cells with pterostilbene for 24 h, and then determine the cell cycle distribution using flow cytometry. HCC: Hepatocellular carcinoma; DNA: DeoxyriboNucleic Acid; HU: Hydroxyurea; MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; EdU: 5-ethyl-2'-deoxyuridine; DAPI: 4',6-Diamidino-2-phenylindole,dihydrochloride. Results are presented as the mean ± SD of triplicate experiments (Student t test, *P < 0.05 and **P < 0.005 vs. the negative control group, ns: no significant difference).
Pterostilbene inhibits HCC and HBV by targeting RRM2

Table 2. Inhibitory effects of Pterostilbene, HU, Sorafenib and COH29 on cell viability in HCC cells

<table>
<thead>
<tr>
<th>Compound</th>
<th>Treatment time (days)</th>
<th>IC₅₀ for cell viability (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>HepG2</td>
</tr>
<tr>
<td>Pterostilbene</td>
<td>3</td>
<td>39.06±4.15</td>
</tr>
<tr>
<td>HU</td>
<td>3</td>
<td>844.10±110.90</td>
</tr>
<tr>
<td>Sorafenib</td>
<td>3</td>
<td>6.33±0.73</td>
</tr>
<tr>
<td>COH29</td>
<td>3</td>
<td>17.19±1.94</td>
</tr>
</tbody>
</table>

IC₅₀: The concentration of compound reduces these HCC cell viability to 50%; HU: Hydroxyurea.

Table 3. Inhibitory effects of Sorafenib and Pterostilbene on cell viability in HepG2-WT and HepG2-SR cells

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC₅₀ for cell viability (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sorafenib</td>
<td>HepG2-WT</td>
</tr>
<tr>
<td>Pterostilbene</td>
<td>1.88±0.72</td>
</tr>
<tr>
<td></td>
<td>34.28±6.26</td>
</tr>
</tbody>
</table>

HepG2-WT: wild-type HepG2; HepG2-SR: sorafenib-resistant HepG2; IC₅₀: The concentration of compound reduces these HCC cell viability to 50%.

Figure 3. Inhibitory effects of pterostilbene on the proliferation of the wild-type and sorafenib-resistant HCC cells. (A) The wild-type (HepG2-WT) and (B) sorafenib-resistant (HepG2-SR) HepG2 cells were treated with a series concentrations of sorafenib or pterostilbene for 72 h, and the cell viability was quantitated by MTT assays. HCC: Hepatocellular carcinoma; MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. Results are presented as the mean ± SD of triplicate experiments.

the effectiveness of 3TC in inhibiting HBV DNA replication of the mutant strain was reduced about 20-fold. Whereas, pterostilbene strongly inhibited the HBV DNA replication of both the wild-type and 3TC-resistant mutant strains, even more potent for the 3TC-resistant HBV strain. In addition, the EC₅₀s for inhibiting HBV DNA replication were about 40-fold lower than the IC₅₀ for the viability of the host HepG2 cells transfected with HBV DNA, also supporting that HBV DNA replication is much more sensitive to pterostilbene than the host HCC cell proliferation.

The inhibitory effects of pterostilbene on RR enzyme activity can be reversed by the addition of dNTP precursors

RR is the unique enzyme to produce dNTPs as substrates for DNA synthesis, addition of the products can counteract the effects of RR inhibition [28]. As dNTPs penetrate cell membranes poorly, a mixture of their precursors (dNs, including thymidine, deoxyadenosine, deoxyguanosine, and deoxycytidine) was used instead. As shown in Figure 5A, the addition of 100 μM dNs reversed the proliferation inhibition of HepG2 and HepG2.2.15 cells by 20 μM pterostilbene. The inhibition of HBV DNA replication in HepG2.2.15 cells was also partially reversed by the addition of 100 μM dNs (Figure 5B). Furthermore, the cell cycle s-phase arrest caused by pterostilbene was reversed as well (Figure 5C). The results showed that the inhibitory effects of pterostilbene can be reversed by addition of dNs, suggesting that RR is the acting target of pterostilbene in the treated cells.
Pterostilbene inhibits HCC and HBV by targeting RRM2

Table 4. Inhibitory effects of Pterostilbene and 3TC on HBV replication and cell viability in HepG2.2.15 cells

<table>
<thead>
<tr>
<th>Compound</th>
<th>EC50 (μM)</th>
<th>IC50 (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pterostilbene</td>
<td>5.65±1.44</td>
<td>22.37±1.68</td>
</tr>
<tr>
<td>3TC</td>
<td>1.42±0.28</td>
<td>&gt;1000</td>
</tr>
</tbody>
</table>

3TC: Lamivudine; EC50: The concentration of compound reduces HBV DNA replication to 50%; IC50: The concentration of compound reduces these HCC cell viability to 50%.

Table 5. Inhibitory effects of Pterostilbene and 3TC on HBV replication and cell viability in HBV transfected HepG2 cells

<table>
<thead>
<tr>
<th>Compound</th>
<th>EC50 (μM)</th>
<th>IC50 (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pterostilbene</td>
<td>0.6±0.16</td>
<td>0.039±0.007</td>
</tr>
<tr>
<td>3TC</td>
<td>≈0.8</td>
<td>17.42±3.09</td>
</tr>
</tbody>
</table>

3TC: Lamivudine; EC50: The concentration of compound reduces HBV DNA replication to 50%; IC50: The concentration of compound reduces these HCC cell viability to 50%; WT: wild-type; Mut: 3TC-resistant-mutant.

Pterostilbine potently inhibits HCC cell growth in tumor xenograft mice with a low toxicity under the treatment doses

To test the effect of pterostilbine on tumour growth in vivo, nude mice were injected with HepG2 cells and treated with 50 or 100 mg/kg/day of pterostilbine for 14 days. The results showed that the pterostilbine treatments significantly decreased HCC cell growth in the nude mice compared with the control group (Figure 6A-C). At the same time, neither mouse body weights nor ALT (Aspartate aminotransferase) and AST (Aspartate aminotransferase) levels were significantly changed between the pterostilbine-treated groups and the solvent control group (Figure 6D and 6E). Moreover, no notable intergroup differences were observed in the important organs of the treated mice, including the heart, liver, spleen, lung, and kidney (Figure 6F). The results indicated a relative...
Pterostilbene inhibits HCC and HBV by targeting RRM2

Figure 5. dNs can reverse the effects of RR inhibition by pterostilbene. A. HepG2 or HepG2.2.15 cells were treated with 100 μM dNs (including thymidine, deoxyadenosine, deoxyguanosine, and deoxycytidine) for 24 h, then further treated by adding a series concentrations of pterostilbene for 72 h, and the cell viability was quantitated by MTT assays. B. Treat the HepG2.2.15 cells with pterostilbene together with 100 μM dNs for 6 days, and the HBV DNA in the cells were detected by Q-PCR measurements. C, D. Treat the HepG2.2.15 cells with pterostilbene at 10 or 20 μM together with 100 μM dNs for 24 h, then the cell-cycle distributions were analyzed using Focusing Cytometer. MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; HBV: Hepatitis B virus; DNA: DeoxyriboNucleic Acid; Q-PCR: Real-time polymerase chain reaction. Results are presented as the mean ± SD of triplicate experiments. *P<0.05, **P<0.005 vs no dNs treated cells by a two-tailed Student's t test.

Discussion

RRM2 expression has been confirmed significantly up-regulated in HCC cells, providing sufficient dNTPs to favor the malignant proliferation [6, 8, 29]. HBV has no RR genes and HBx can activate RRM2 expression in the host liver cells for the viral DNA replication [10]. HBV infection is a causative factor of HCC and associated with HCC development and prognosis. We have previously demonstrated that RR is essential for HBV genomic DNA and cccDNA synthesis in HCC cells, and RR enzyme activity is up-regulated in the liver tissues of HBV genome-transgenic mice [11]. These findings suggest that RR, HBV, and HCC may form a mutual-promoting vicious triangle during HBV-related HCC development.

In this study, for the first time pterostilbene was identified as a novel RRM2 inhibitor (Figure 1). RR enzyme assays showed that the compound possessed about 20-fold and 200-fold higher activity for RR inhibition than that of COH29 (the most effective RRM2 inhibitory drug in an anti-cancer phase I clinical trial) and HU (the classical RRM2 inhibitory drug), respectively. The higher RR inhibitory activity may indicate a higher specificity for RRM2 and a lower off-target effect of pterostilbene. Pterostilbene potently inhibited HCC proliferation and HBV...
Pterostilbene inhibits HCC and HBV by targeting RRM2

Figure 6. Pterostilbine attenuates HCC cell growth in xenograft nude mice with a relative low toxicity. A, B. 18 nude mice were subcutaneously injected with $1 \times 10^7$ HepG2 cells, and 6 mice were used in each of the three groups for pterostilbine treatments (50 and 100 mg/kg) or the solvent DMSO control by daily i.p. injection for two weeks. The weights and sizes of the tumor xenografts in nude mice were measured. C. Images of the xenograft tumors in nude mice. D. Body weight changes of the three-group nude mice. E. ALT and AST levels in the sera of the three-group nude mice were tested by the method showed in the section 2.15. F. Representative images of pathological examinations with H&E staining ($\times$ 200). HCC: Hepatocellular carcinoma; DMSO: Dimethyl sulfoxide; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase. Results are presented as the mean ± SD of 6 mice in each group. $P$ values were determined by a two-tailed Student’s $t$ test. *$P < 0.05$, **$P < 0.005$ vs the vehicle-treated mice.
DNA replication in HCC cells (Figures 2 and 4), while the both inhibitory effects were significantly reversed by the addition of dNTP precursors, indicating that RR was the intracellular action target of pterostilbene (Figures 1F, 1G and 5).

Pterostilbene inhibited in vitro HCC proliferation with a MTT IC$_{50}$ of about 20-40 μM, resulted from the inhibition of RR, the rate-limiting enzyme in the synthesis of dNTPs, leading to DNA synthesis blocking, cell cycle arrest, and finally apoptosis (Figure 2). The inhibitory potency was similar to COH29 but a little lower than sorafenib (Figure 2). Since 2007, sorafenib, a multi-kinase (serine, threonine, and tyrosine kinases) inhibitor, has been used as a clinical first-line targeted drug for HCC systemic therapy, but the overall survival rate is limited and the treated patients frequently developed resistance to sorafenib. Our data demonstrated that pterostilbene can overcome the sorafenib-resistance of HCC cells (Figure 3). Tumor xenograft mouse model assays showed that pterostilbene markedly inhibited HCC tumor growth with a relatively low toxicity under therapeutic doses in vivo (Figure 6), suggesting a potential use of the compound for HCC treatment, especially for sorafenib-resistant HCC.

On the other hand, pterostilbene significantly inhibited HBV DNA replication in both the HBV genome-integrated HCC cell line HepG2.2.15 and the HCC cell line HepG2 newly transfected with HBV DNA (Figure 4). The EC$_{50}$ values of the compound for inhibiting HBV DNA replication were about 4-fold and 40-fold lower than its MTT IC$_{50}$ values for inhibiting the host HCC proliferation in the two cell lines, respectively. The results suggested that the inhibition of HBV replication did not result from the death of the host cells. Further, HBV replicates quickly in the infected liver cells, consuming a large amount of dNTPs for its genome synthesis, which may explain why HBV replication was more vulnerable to RR inhibition by pterostilbene than its host HCC proliferation [9]. Interestingly, pterostilbene more potently inhibited the HBV-genome integrated HCC cell line HepG2.2.15 than HU and COH29 (Figure 2), possibly due to its higher specificity for RRM2 inhibition. Also importantly, while the HBV replication inhibitory activity of pterostilbene was close to that of lamivudine, it effectively overcame the resistance to the anti-HBV drug (Figure 4), a recurrent clinical problem during the long term anti-HBV treatment. The target and action mechanism of pterostilbene are different from lamivudine and sorafenib, which may explain its efficacy in overcoming the resistance to the two drugs.

In summary, this research shows that inhibition of RR has the double effects against both HBV replication and HCC proliferation. Pterostilbene is a novel potent and specific RR inhibitor through interacting with RRM2 protein. The compound possesses much higher activity against in vitro RR enzyme activity and in vivo HCC xenograft growth than current RRM2 inhibitory drugs. It can significantly simultaneously inhibit both HCC proliferation and HBV replication by RR inhibition with the potencies comparable to the anti-HCC drug sorafenib and the anti-HBV drug lamivudine, respectively. Furthermore, the compound can overcome the frequent drug-resistant problems with sorafenib and lamivudine. So far, no single drug has been reported to possess both activities against HBV and HCC. Thus, pterostilbene, as an available natural product or synthesized compound, or through further optimization, may prove to be a potential new drug for treatment of the HCC and especially HBV-related HCC in the future.

Acknowledgements

This work was supported by National Natural Science Foundation of China (81372138, 81972270, 81572384, and 81771518), National Science and Technology Major Project of China (2018ZX10302206-006-007), and National Key R&D Program of China (2016-YFC1303401).

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Jimin Shao, Department of Pathology & Pathophysiology, and Cancer Institute of The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Tel: +86-13732221892; Fax: +86-0571-88208209; E-mail: shaojimin@zju.edu.cn; Weiliang Zhu, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, China. Tel: +86-13681867996; Fax: +86-21-50807088; E-mail: wzlzhu@simm.ac.cn
Pterostilbene inhibits HCC and HBV by targeting RRM2

References

[2] de Martel C, Maucourt-Bouch D, Plummer M and Franceschi S. World-wide relative contribu-
tion of hepatitis B and C viruses in hepatocel-
lular carcinoma. Hepatology 2015; 62: 1190-
1200.
low SD. NCCN guidelines insights: hepatobi-
[4] Kang G, Taguchi AT, Stubbe J and Drennan CL. Structure of a trapped radical transfer pathway within a ribonucleotide reductase holocom-
nucleotide reductase for cancer therapy. Ex-
opin Ther Targets 2013; 17: 1423-1437.
tide reductase and cancer: biological mecha-
tional phosphoprotein network construction and analysis between no-tumor hepatitis/cir-
[9] Gearhart TL and Bouchard MJ. Replication of the hepatitis B virus requires a calcium-depen-
dent HBx-induced G1 phase arrest of hepato-
[10] Cohen D, Adamovich Y, Reuven N and Shaul Y. Hepatitis B virus activates deoxynucleot-
side synthesis in nondividing hepatocytes by target-
ning the R2 gene. Hepatology 2010; 51: 1538-
1546.
[12] Xu J, Zhang J, Shan F, Wen J and Wang Y. SSTR5-AS1 functions as a ceRNA to regulate CA2 by sponging miR-15b-5p for the develop-
ment and prognosis of HBV-related hepatocel-
[13] Levin VA. The place of hydroxyurea in the treat-
parison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of sur-
[16] Platt OS. Hydroxyurea for the treatment of sick-
le cell anemia. N Engl J Med 2008; 358: 1362-
1369.
tide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resis-
[19] Lin HS, Yue BD and Ho PC. Determination of pterostilbene in rat plasma by a simple HPLC-
Pterostilbene inhibits HCC and HBV by targeting RRM2


[27] Luo L, Shen L, Sun F and Ma Z. Immunoprecipitation coupled with HPLC-MS/MS to discover the aromatase ligands from Glycyrrhiza uralensis. Food Chemistry 2013; 138: 315-320.


Pterostilbene inhibits HCC and HBV by targeting RRM2

Figure S1. A. HepG2.2.15 cells were transfected with FLAG-EV or FLAG-JMJD5 expression plasmids, then the cells were treated with or without 20 μM pterostilbene for 24 h. The cell lysates were analyzed by immunoprecipitation using anti-FLAG magnetic beads followed by western blotting with FLAG antibody. B. The pterostilbene bounded to the eluted protein was detected by HPLC/MS/MS, retention time for pterostilbene was 3.34 min. IP, immunoprecipitation.